Journal Guide

The journal provides a unique forum for scientific publication of high-quality research that is exclusively focused on translational aspects of drug delivery. Rationally developed, effective delivery systems can potentially affect clinical outcome in different disease conditions. Research focused on the following areas of translational drug delivery research will be considered for publication in the journal. Designing and developing novel drug delivery systems, with a focus on their application to disease conditions: Preclinical and clinical data related to drug delivery systems: Drug distribution, pharmacokinetics, clearance, with drug delivery systems as compared to traditional dosing to demonstrate beneficial outcomes Short-term and long-term biocompatibility of drug delivery systems, host response: Biomaterials with growth factors for stem-cell differentiation in regenerative medicine and tissue engineering: Image-guided drug therapy, Nanomedicine: Devices for drug delivery and drug/device combination products. In addition to original full-length papers, communications, and reviews, the journal includes editorials, reports of future meetings, research highlights, and announcements pertaining to the activities of the Controlled Release Society.

Drug Discovery Today delivers informed and highly current reviews for the discovery community. The magazine addresses not only the rapid scientific developments in drug discovery associated technologies but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed.Features include comment by international experts, news and analysis of important developments, reviews of key scientific and strategic issues, overviews of recent progress in specific therapeutic areas and conference reports.Coverage includes:• Novel therapeutic strategies• High-throughput screening• Therapeutic targets• Combinatorial chemistry, parallel synthesis and library design• Drug delivery• ADME/Tox• Advances in key compound classes and therapeutic areas• Genomics and proteomics• Automation and technology• Virtual chemistry• Informatics• Business strategy• Clinical trialsand other aspects of drug discovery.Ethics in Publishing: General StatementThe Editor(s) and Publisher of this Journal believe that there are fundamental principles underlying scholarly or professional publishing. While this may not amount to a formal 'code of conduct', these fundamental principles with respect to the authors' paper are that the paper should: i) be the authors' own original work, which has not been previously published elsewhere, ii) reflect the authors' own research and analysis and do so in a truthful and complete manner, iii) properly credit the meaningful contributions of co-authors and co-researchers, iv) not be submitted to more than one journal for consideration, and v) be appropriately placed in the context of prior and existing research. Of equal importance are ethical guidelines dealing with research methods and research funding, including issues dealing with informed consent, research subject privacy rights, conflicts of interest, and sources of funding. While it may not be possible to draft a 'code' that applies adequately to all instances and circumstances, we believe it useful to outline our expectations of authors and procedures that the Journal will employ in the event of questions concerning author conduct. With respect to conflicts of interest, the Publisher now requires authors to declare any conflicts of interest that relate to papers accepted for publication in this Journal. A conflict of interest may exist when an author or the author's institution has a financial or other relationship with other people or organizations that may inappropriately influence the author's work. A conflict can be actual or potential and full disclosure to the Journal is the safest course. All submissions to the Journal must include disclosure of all relationships that could be viewed as presenting a potential conflict of interest. The Journal may use such information as a basis for editorial decisions and may publish such disclosures if they are believed to be important to readers in judging the manuscript. A decision may be made by the Journal not to publish on the basis of the declared conflict.For more information, please refer to: http://www.elsevier.com/wps/find/authorshome.authors/conflictsofinterestSubmission to Drug Discovery Today is by invitation only. If you are interested in submitting an article please first send us a proposal with a brief description of the main theme of the article (approx. 100 - 200 words), listing the article type and if possible some key references. Information on how to submit a proposal can be found at:http://www.drugdiscoverytoday.com/submit-a-paper/

The Drug Discovery Today reviews collection provides a resource of review content aligning the key output of human molecular medicine with the specific requirements of the drug discovery process. It is designed to systematically cover the essential elements of molecular medicine and drug discovery, in a manner that has relevance to those actually working on the discovery and development of new drugs. This collection will evolve to create a highly structured database and will act as a one-stop-shop for high quality content.Other titles in this series include:Drug Discovery Today: Disease ModelsDrug Discovery Today: Therapeutic StrategiesDrug Discovery Today: TechnologiesDrug Discovery Today: Disease Mechanisms covers the analysis of the molecules and pathways that fail or are subverted during the aetiology and pathogenesis of human disease. It focuses on what is actually known or strongly predicted about the human disease process.There will be 4 issues each year. The Drug Discovery Today reviews collection is only available online.Ethics in Publishing: General StatementThe Editor(s) and Publisher of this Journal believe that there are fundamental principles underlying scholarly or professional publishing. While this may not amount to a formal 'code of conduct', these fundamental principles with respect to the authors' paper are that the paper should: i) be the authors' own original work, which has not been previously published elsewhere, ii) reflect the authors' own research and analysis and do so in a truthful and complete manner, iii) properly credit the meaningful contributions of co-authors and co-researchers, iv) not be submitted to more than one journal for consideration, and v) be appropriately placed in the context of prior and existing research. Of equal importance are ethical guidelines dealing with research methods and research funding, including issues dealing with informed consent, research subject privacy rights, conflicts of interest, and sources of funding. While it may not be possible to draft a 'code' that applies adequately to all instances and circumstances, we believe it useful to outline our expectations of authors and procedures that the Journal will employ in the event of questions concerning author conduct. With respect to conflicts of interest, the Publisher now requires authors to declare any conflicts of interest that relate to papers accepted for publication in this Journal. A conflict of interest may exist when an author or the author's institution has a financial or other relationship with other people or organizations that may inappropriately influence the author's work. A conflict can be actual or potential and full disclosure to the Journal is the safest course. All submissions to the Journal must include disclosure of all relationships that could be viewed as presenting a potential conflict of interest. The Journal may use such information as a basis for editorial decisions and may publish such disclosures if they are believed to be important to readers in judging the manuscript. A decision may be made by the Journal not to publish on the basis of the declared conflict. For more information, please refer to: http://www.elsevier.com/wps/find/authorshome.authors/conflictsofinterest.

The Drug Discovery Today reviews collection provides a resource of review content aligning the key output of human molecular medicine with the specific requirements of the drug discovery process. It is designed to systematically cover the essential elements of molecular medicine and drug discovery, in a manner that has relevance to those actually working on the discovery and development of new drugs. This collection will evolve to create a highly structured database and will act as a one-stop-shop for high quality content.Drug Discovery Today: Disease Models discusses the non-human experimental models through which inference is drawn regarding the molecular aetiology and pathogenesis of human disease. It provides critical analysis and evaluation of which models can genuinely inform the research community about the direct process of human disease, those which may have value in basic toxicology, and those which are simply designed for effective expression and raw characterisation.Other titles in this series include:Drug Discovery Today: Disease MechanismsDrug Discovery Today: Therapeutic StrategiesDrug Discovery Today: TechnologiesThere will be four issues each year.The Drug Discovery Today reviews collection is only available online.Ethics in Publishing: General StatementThe Editor(s) and Publisher of this Journal believe that there are fundamental principles underlying scholarly or professional publishing. While this may not amount to a formal 'code of conduct', these fundamental principles with respect to the authors' paper are that the paper should: i) be the authors' own original work, which has not been previously published elsewhere, ii) reflect the authors' own research and analysis and do so in a truthful and complete manner, iii) properly credit the meaningful contributions of co-authors and co-researchers, iv) not be submitted to more than one journal for consideration, and v) be appropriately placed in the context of prior and existing research. Of equal importance are ethical guidelines dealing with research methods and research funding, including issues dealing with informed consent, research subject privacy rights, conflicts of interest, and sources of funding. While it may not be possible to draft a 'code' that applies adequately to all instances and circumstances, we believe it useful to outline our expectations of authors and procedures that the Journal will employ in the event of questions concerning author conduct. With respect to conflicts of interest, the Publisher now requires authors to declare any conflicts of interest that relate to papers accepted for publication in this Journal. A conflict of interest may exist when an author or the author's institution has a financial or other relationship with other people or organizations that may inappropriately influence the author's work. A conflict can be actual or potential and full disclosure to the Journal is the safest course. All submissions to the Journal must include disclosure of all relationships that could be viewed as presenting a potential conflict of interest. The Journal may use such information as a basis for editorial decisions and may publish such disclosures if they are believed to be important to readers in judging the manuscript. A decision may be made by the Journal not to publish on the basis of the declared conflict.For more information, please refer to: http://www.elsevier.com/wps/find/authorshome.authors/conflictsofinterest

The Drug Discovery Today reviews collection provides a resource of review content aligning the key output of human molecular medicine with the specific requirements of the drug discovery process. It is designed to systematically cover the essential elements of molecular medicine and drug discovery, in a manner that has relevance to those actually working on the discovery and development of new drugs. This collection will evolve to create a highly structured database and will act as a one-stop-shop for high quality content.

The Drug Discovery Today reviews collection provides a resource of review content aligning the key output of human molecular medicine with the specific requirements of the drug discovery process. It is designed to systematically cover the essential elements of molecular medicine and drug discovery, in a manner that has relevance to those actually working on the discovery and development of new drugs.This collection will evolve to create a highly structured database and will act as a one-stop-shop for high quality content.What are the biotechnical challenges in ensuring drug action, especially with regard to biopharmaceuticals? Drug Discovery Today: Therapeutic Strategies discusses the varied strategies used, including stem-cell therapy, vaccination, gene therapy, tissue modelling, tissue and non-tissue implants and many others.Other titles in this series include:Drug Discovery Today: Disease MechanismsDrug Discovery Today: Disease ModelsDrug Discovery Today: TechnologiesThere will be four issues each year. The Drug Discovery Today reviews collection is only available online.Ethics in Publishing: General StatementThe Editor(s) and Publisher of this Journal believe that there are fundamental principles underlying scholarly or professional publishing. While this may not amount to a formal 'code of conduct', these fundamental principles with respect to the authors' paper are that the paper should: i) be the authors' own original work, which has not been previously published elsewhere, ii) reflect the authors' own research and analysis and do so in a truthful and complete manner, iii) properly credit the meaningful contributions of co-authors and co-researchers, iv) not be submitted to more than one journal for consideration, and v) be appropriately placed in the context of prior and existing research. Of equal importance are ethical guidelines dealing with research methods and research funding, including issues dealing with informed consent, research subject privacy rights, conflicts of interest, and sources of funding. While it may not be possible to draft a 'code' that applies adequately to all instances and circumstances, we believe it useful to outline our expectations of authors and procedures that the Journal will employ in the event of questions concerning author conduct. With respect to conflicts of interest, the Publisher now requires authors to declare any conflicts of interest that relate to papers accepted for publication in this Journal. A conflict of interest may exist when an author or the author's institution has a financial or other relationship with other people or organizations that may inappropriately influence the author's work. A conflict can be actual or potential and full disclosure to the Journal is the safest course. All submissions to the Journal must include disclosure of all relationships that could be viewed as presenting a potential conflict of interest. The Journal may use such information as a basis for editorial decisions and may publish such disclosures if they are believed to be important to readers in judging the manuscript. A decision may be made by the Journal not to publish on the basis of the declared conflict. For more information, please refer to: http://www.elsevier.com/wps/find/authorshome.authors/conflictsofinterest.

Drug Metabolism Letters publishes letters, original research articles, mini-reviews, thematic issues based on mini-reviews and letters, commentaries, technical notes and drug clinical trial studies on major advances in all areas of drug metabolism and disposition.

Drug Metabolism Reviews consistently provides critically needed reviews of an impressive array of drug metabolism research-covering established, new, and potential drugs; environmentally toxic chemicals; absorption; metabolism and excretion; and enzymology of all living species. Additionally, the journal offers new hypotheses of interest to diverse groups of medical professionals including pharmacologists, toxicologists, chemists, microbiologists, pharmacokineticists, immunologists, mass spectroscopists, as well as enzymologists working in xenobiotic biotransformation.

An important reference for all pharmacology and toxicology departments, DMD is also a valuable resource for medicinal chemists involved in drug design and biochemists with an interest in drug metabolism, expression of drug metabolizing enzymes, and regulation of drug metabolizing enzyme gene expression. Articles provide experimental results from in vitro and in vivo systems that bring you significant and original information on metabolism and disposition of endogenous and exogenous compounds, including pharmacologic agents and environmental chemicals.

Thank you for your cooperation. (The degraded operation period has changed.

Drug Resistance Updates is a bimonthly publication that contains thought-provoking reviews on important developments in drug resistance in infectious disease and cancer as well as novel drugs and strategies to overcome drug resistance.It covers both basic research and clinical aspects of drug resistance, and involves disciplines as diverse as molecular biology, biochemistry, cell biology, pharmacology, microbiology, preclinical therapeutics, oncology and clinical medicine.Articles are written by leaders in the field, in response to an invitation from the Editors, and are peer-reviewed prior to publication. Articles are clear, readable, and up-to-date, suitable for a multidisciplinary readership and include schematic diagrams and other illustrations conveying the major points of the article. The goal is to highlight recent areas of growth and put them in perspective.*Expert reviews in clinical and basic drug resistance research in oncology and infectious disease *Describes emerging technologies and therapies, particularly those that overcome drug resistance *Emphasises common themes in microbial and cancer research

Drug Safety is the official journal of the International Society of Pharmacovigilance. The journal includes:   

• Overviews of contentious or emerging issues. 
• Comprehensive narrative reviews that provide an authoritative source of information on epidemiology, clinical features, prevention and management of adverse effects of individual drugs and drug classes. 
• In-depth benefit-risk assessment of adverse effect and efficacy data for a drug in a defined therapeutic area. 
• Systematic reviews (with or without meta-analyses) that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by the PRISMA statement.
• Original research articles reporting the results of well-designed studies in disciplines such as pharmacoepidemiology, pharmacovigilance, pharmacology and toxicology, and pharmacogenomics.
• Editorials and commentaries on topical issues.